This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Endothelium-specific gene and stem cell-based therapy for
erectile dysfunction
Travis D. Strong1, Milena A.
Gebska2, Arthur L. Burnett1, Hunter C.
Champion2, Trinity J. Bivalacqua1
1The Brady Urological Institute, Department of Urology, Johns Hopkins Hospital, Baltimore, MD 21287, USA
2Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD 21287, USA
Abstract
Erectile dysfunction (ED) commonly results from endothelial dysfunction of the systemic vasculature. Although
phosphodiesterase type 5 (PDE-5) inhibitors are effective at treating most cases of ED, they must be taken routinely
and are ineffectual for a meaningful number of men. In recent years gene and stem cell-based therapies targeted at the
penile endothelium have been gaining momentum in preclinical studies. These early studies reveal that gene and stem
cell-based therapies may be both enduring and efficacious, and may eventually lead to a cure for ED. The following
review will highlight our current understanding of endothelial-specific gene and stem cell-based therapies performed
to date in a number of experimental animal models.
(Asian J Androl 2008 Jan; 10: 14_22)
Keywords: erectile dysfunction; endothelial-specific gene; endothelial dysfunction; gene therapy
Correspondence to: Dr Trinity J. Bivalacqua, The Brady Urological Institute, Department of Urology, Johns Hopkins Hospital, 600 N.
Wolfe Ave., Marburg 143 Baltimore, MD 21287, USA.
Tel: +1-410-955-0352 Fax: +1-410-614-3695
E-mail: tbivala1@jhmi.edu
DOI: 10.1111/j.1745-7262.2008.00362.x
1 Introduction
Erectile dysfunction (ED) is defined as the persistent inability to achieve and maintain an erection of sufficient
quality to permit satisfactory sexual intercourse [1]. In recent years, a growing number of studies have elucidated the
role of the endothelium in the normal physiology of erections, as well as the pathophysiology of ED [2, 3]. Once
believed to serve as only a passive barrier, the endothelium is now considered a primary mediator of vascular blood
flow and muscle tone, as directed by neural, humoral, and mechanical stimuli.
As principally a disease of vascular origin, ED correlates highly in men with hypercholesterolemia, cardiovascular
disease, hypertension, and diabetes mellitus [4]. Linking these conditions is the presence of endothelial dysfunction,
a pathological state of the vasculature involving the loss of the endothelium's responsiveness to vasodilator mediators
or an increase in sensitivity to vasoconstrictors. Because ED generally presages or presents concurrently with
cardiovascular risk factors, and because cardiovascular disease has been clearly associated with endothelial dysfunction,
it is reasonable to infer that ED may result from endothelial dysfunction of the penile vasculature [5, 6]. A number of
both clinical and preclinical studies on hypercholesterolemia, hyptertension, diabetes, and aging have demonstrated
endothelial dysfunction to be a critical factor in the development of vasculogenic ED [7].
Endothelial dysfunction broadly refers to any pathological condition that inhibits the homeostatic activities of the
endothelium, though the term generally connotes an attenuated endothelium-dependent smooth muscle relaxation
resulting from diminished nitric oxide (NO) bioavailability within the vasculature. Although ED may be caused by an
array of etiologies, endothelial dysfunction plays a preponderant role in a significant number of vasculogenic ED
cases. Endothelial dysfunction within the penis is characterized by endothelial NO synthase (eNOS) uncoupling,
abnormal eNOS expression and regulation, lack of eNOS substrate or cofactors, and increased oxidative stress with
concomitant degradation of NO [8]. Responses to NO donors such as sodium nitroprusside in the presence of
endothelial dysfunction demonstrates that the machinery for vasodilation often remains intact and that
endothelium-specific aberrations are responsible for the diminished bioavailability of NO.
Despite the profound success of current
pharmacotherapy for ED, there remains an appreciable contingent
of men with intractable ED. The vascular damage
accompanying diabetes, for instance, is often too
disruptive to endothelial physiology to permit adequate erections,
even with pharmacological intervention. It is therefore
imperative to find novel ways to combat
endothelial-dependent ED. Recently, preclinical studies with gene and
stem cell therapies targeting the vascular endothelium in
the penis have proven promising (Table 1). It is the
intent of this review to survey these early studies and to
foster interest into this burgeoning field of research.
2 Gene therapy for ED
The idea of gene therapy arose gradually in the 1960s
and 1970s, with the first clinical experiment conducted
in 1970 using the Shope papillomavirus to deliver
arginase to two girls with arginemia [9]. Like many early
attempts at gene therapy, this experiment failed but
beckoned in an era of intensive preclinical and clinical
evaluations of the concept, leading to the first clinical gene
therapy cure in 2000 [10]. Introduction of exogenous
genes may be accomplished through a number of vectors
ranging from the viral (e.g. retroviruses, adenoviruses
[Adv], Sinbisviruses) to the nonviral (e.g. liposomes or
naked DNA, gold nanoparticles), though
replication-deficient retroviruses, adenoviruses, and adeno-associated
viruses (AAV) currently predominate most gene therapy studies
in the literature. Primary drawbacks to gene therapy are
random transgene expression and insertional mutagenesis.
Owing to its external positioning and limited blood
flow that would hinder non-target infection in the
systemic circulation, the penis is an amenable structure for
gene therapy [11, 12]. In addition, cells within the penis,
particularly vascular smooth muscle cells, appear to have
a relatively low turnover rate. This may allow long-term
expression of introduced genes and thus a more
enduring therapeutic option to current pharmacological agents.
Another potential benefit of gene therapy for ED is the
directed correction of any aberrant biochemical pathway
that manifests as penile vascular dysfunction. A number
of deviant biochemical pathways are acknowledged to
lead to ED, and as long as a therapeutic gene exists that
can enhance or replace deficient functions it is
theoretically possible to introduce the reparative gene [13].
Currently, gene therapy for ED has emphasized the
NO/cGMP/protein kinase G (PKG) pathway, reflecting the
principal role of NO bioavailability in the achievement
and maintenance of erections [14, 15]. However, a
diverse group of introduced genes corresponding to an
array of biochemical pathways have shown promising
preclinical results as well. In addition, a recent Phase I
clinical study has established the safety and apparent
efficacy of gene therapy for ED using the human smooth
muscle Maxi-K channel [16]. Because the corporal
endothelium is a key mediator of penile NO, many gene
therapies have focused on repairing deficient endothelial
NO production (Figure 1A).
2.1 eNOS gene therapy
Chiefly expressed within the endothelium, eNOS plays a vital role throughout the systemic vasculature in
producing NO necessary for smooth muscle relaxation
[17]. Several studies have considered eNOS gene therapy
for various vascular pathologies with promising results
[18_22]. In the penis, eNOS functions to maintain
erections by supplying a prolonged release of NO to the
overlying smooth muscle cells [2]. Diminished expression
or abnormal post-translational modification of eNOS has
been documented within the corpora cavernosa in a
number of animal models of aging, hypercholesterolemia,
hypertension, and diabetes [8]. Accordingly, attenuated
activity of eNOS leads to increased vascular tone and
tendencies to developing ED.
The critical role of eNOS in regulating erectile
physiology has inspired a number of studies evaluating virally
introduced eNOS to the corpora cavernosa. In a rat
model of age-related ED, it was found that adenoviral
gene transfer of eNOS was able to enhance erectile
responses to cavernous nerve stimulation, acetylcholine,
and a phosphodiesterase type 5 (PDE-5) inhibitor [20].
From this and other studies, adenoviral overexpression
of eNOS increases eNOS mRNA and protein expression,
as well as the predominant second messenger cGMP, within the aged penis [23]. Similarly, in a rat model of
diabetic-associated ED, intracavernous eNOS
transduction resulted in rectified erectile responses to cavernous
nerve stimulation and increased corporal NO bioavailability
[24]. In an analogous study, Bivalacqua et
al. [25] demonstrated synergistic effects of intracavernous eNOS
transduction and acute systemic administration of the
PDE-5 inhibitor sildenafil on increasing erectile function
and cGMP levels within diabetic rat penes. Paradoxically,
eNOS knockout mice are subject to priapism, a
consequence of downregulated PDE-5 expression with the
resultant inability to break down even modest levels of
cGMP [26, 27]. In an eNOS knockout mouse model of
priapism, gene transfer of eNOS resulted in normalized
PDE-5 expression and correction of priapic activity,
providing an example of the utility of eNOS gene transfer
technology to further study endothelial function [27].
2.2 Vascular endothelial growth factor (VEGF) gene
therapy
One of the more intriguing determinants of erectile
biology is the growth factor, VEGF. VEGF is a critical
mediator of endothelial and smooth muscle physiology,
and VEGF reduction is associated with a number of
pathophysiological changes in the penis. In various models of
ED, VEGF, as well as its receptor, flk-1, are
down-regulated [28_30]. Given the critical role of VEGF in erectile
biology, several studies have considered whether VEGF
protein therapy ameliorates vasculogenic ED. In the first
study of its kind, Henry et al. [31] evaluated the effects
of VEGF protein delivery in an atherosclerotic rabbit
model of ED and concluded that intracavernous
injections of VEGF seemed to protect the penile corporal
endothelium against the damaging effects of
hypercholesterolemia. Corroborating this result, another study
considering hypercholesterolemia-induced ED found evidence of
hyperplasia and hypertrophy within the endothelium
following intracavernous VEGF protein delivery,
suggestive of active angiogenesis [32]. Animals not receiving
intracavernous VEGF, however, displayed endothelial
denudation and platelet attachment in the sinusoids.
Further studies have shown a protective effect of
intracavernously delivered VEGF protein in traumatic arteriogenic and
diabetic models of ED [33_36].
These studies and others have largely elucidated the
mechanisms by which VEGF exerts its protective effects on the corporal endothelium. Owing to its
mitogenic properties, VEGF induces hyperplasia and
hypertrophy of endothelial cells, which may counteract the
endothelial apoptosis common to some manifestations of
ED [34]. VEGF may also directly induce anti-apoptotic
pathways within the endothelium [35]. In addition, VEGF
protects the endothelial response to acetylcholine, restores
levels of sex hormone receptors, increases expression
of eNOS, and directs stimulatory eNOS phosphorylation
[31, 34, 36, 37].
Built upon the demonstrable evidence that VEGF
protein therapy enhances erectile responses in disease models,
along with a mechanistic understanding of how VEGF
improves endothelial physiology, several recent studies
have evaluated VEGF gene therapy for ED. The general
intent of these studies was to ascertain whether
introduced VEGF DNA would result in the long-term
expression of VEGF, perhaps serving as a curative or near
curative treatment for vasculogenic ED. In a model of
venogenic ED resulting from castration, intracavernous
delivery of VEGF mediated by AAV induced endothelial
cell hyperplasia and hypertrophy, suggestive of active
angiogenesis [38]. Furthermore, intracavernous
AAV-VEGF delivery at the time of castration prevented venous
leak and ED. Subsequently, it was discovered that
intracavernous delivery of VEGF by Adv in a venogenic
model of ED increases the phosphorylation of eNOS at
Serine 1177, greatly enhancing NO production [37].
Adv-VEGF treated mice also demonstrated a recovery in
erectile function. In contrast to wild-type mice, eNOS
knockout mice were non-responsive to Adv-VEGF therapy,
demonstrating a paramount role of eNOS in mediating
the beneficial effects of VEGF. In a recent study of
hypercholesterolemia-associated ED, intracavernous
Adv-VEGF delivery greatly enhanced endothelial content of
the corporal sinusoids. When combined with Adv-angiopoietin-1 (Adv-Ang1), Adv-VEGF markedly
increased factor VIII-positive endothelial density within the
penes of hypercholesterolemic rats. Additionally, the ratio
of phospho-eNOS (Ser1177) to total eNOS was strikingly
higher in hypercholesterolemic rats receiving Adv-VEGF
or Adv-VEGF + Adv-Ang1 treatment. Underscoring the
critical role of the endothelium in erectile physiology,
Adv-VEGF alone and combined with Adv-Ang1 significantly
increased erectile responses to electrical stimulation [39].
2.3 Extracellular superoxide dismutase (EC-SOD) gene
therapy
Oxidative stress has been cogently demonstrated as
a mediator of endothelial dysfunction within the systemic
vasculature and of erectile dysfunction in the penis [40].
Reactive oxygen species (ROS), most notably superoxide,
scavenge NO, forming the highly toxic peroxynitrite.
Both superoxide and peroxynitrite serve to uncouple
eNOS within the endothelium, which leads to yet further
production of ROS. In addition, inducible nitric oxide
synthase (iNOS), the Ca-independent NOS isoform, is
expressed in endothelial cells under stressed conditions
and further contributes to ROS production [41].
Endogenous enzymes, such as NADPH oxidase and xanthine oxidase, expressly produce ROS and are often
elevated in diseases associated with endothelial dysfunction.
Combating the pernicious effects of ROS are endogenous
antioxidants and enzymes such as SOD. SOD catalyzes
the dismutation of superoxide into hydrogen peroxide and
water and is expressed in a number of cells including the
vascular endothelium.
Several studies have considered the potential
therapeutic effect of introducing SOD through gene therapy
to quench ROS. Virally delivered SOD has yielded
therapeutic effects in models of hypertension,
hypercholesterolemia, heart failure, and aging
[42_45]. Considering that the penile endothelium is a microcosm of the systemic
vascular endothelium, a small number of pioneering
studies have evaluated the therapeutic potential of intracavernous
adenoviral gene transfer of EC-SOD, the predominant
SOD isoform found in the vessel wall of the systemic
vasculature. In a model of age-related ED in rats,
Bivalacqua et al. [46] described increased superoxide
production, diminished erectile responses to cavernous
nerve stimulation and endothelium dependent agonists,
elevated nitrotyrosine staining (a measure of oxidative
stress), and reduced cGMP production in aged cavernous tissue. However, there was no commensurate
increase in EC-SOD to combat the heightened superoxide
levels. Upon administration of virally-introduced EC-SOD,
EC-SOD mRNA, protein, and activity levels markedly
increased. Furthermore, cGMP levels improved while
nitrotyrosine staining within the endothelium declined.
These molecular data were corroborated by salient
improvements in erectile responses to cavernous nerve
stimulation, as well as the endothelium-dependent
vasodilator acetylcholine, demonstrating that EC-SOD gene
therapy may alleviate ROS damage within the penile
endothelium and restore erectile function.
Diabetes mellitus is an intricate disease with a
constellation of pathophysiological etiologies and sequelae.
As with age, strong evidence indicates that enhanced
ROS, particularly superoxide, is a critical mediator of
diabetes-related vascular dysfunction [47, 48].
Endothelial dysfunction as a result of diabetes in the penile
vascular bed may be a result of ROS generation, thus
decreasing NO bioavailability [49_51]. Bivalacqua
et al. [51] attempted to discern whether EC-SOD gene therapy
could moderate the levels of superoxide in the diabetic
penis, as well as improve physiological measurements of
erectile function. The authors noted that in the diabetic
penis, EC-SOD expression was insufficient to reduce
superoxide production, and that overexpression of
EC-SOD using an adenoviral vector attenuated superoxide
levels, increased cGMP production, and significantly
improved erectile physiology. These data suggest that
reduction of superoxide anion improves erectile
physiology through an endothelium-dependent manner
secondary to improved corporal cGMP production.
2.4 Molecular targets indirectly affecting penile
endothelium
Any agent that acts to increase penile blood flow will
indirectly improve corporal endothelial physiology via
phosphorylation of the eNOS enzyme and increased
production of endothelial-derived NO. A number of gene
therapies aimed at correcting neuronal or smooth muscle
physiology therefore may improve endothelial function
within the penis. Briefly, intracavernous gene delivery
of ion channels (maxi-K channel), brain derived
neurotrophic factor (BDNF), calcitonin gene-related peptide
(CGRP), penile neuronal NOS (PnNOS), vasoactive intestinal peptide (VIP), insulin-like growth factor-1
(IGF-1), and PKG have all demonstrated promising preclinical
efficacy at remedying ED and increasing blood flow to the
penis [15, 52_57]. Irrespective of the mechanism,
increased vascular shear stress resulting from enhanced
penile blood flow may lead to phosphorylation of eNOS
and improve endothelial derived NO biosynthesis. However, these conclusions are purely speculative at this
time and need further investigation. In one of the earliest
studies, iNOS was shown to demonstrate improvements
to erectile physiology [58]. However, iNOS is not a
normal component of penile erection and may lead to
increased ROS [59]. Furthermore, inducible NOS (iNOS)
has been shown to cause endothelial dysfunction of the
penile vascular bed [60].
3 Future of gene therapy for ED
Although the present preclinical gene therapy studies
have demonstrated efficacy, there are a number of
drawbacks that may limit their clinical implementation. First,
the viral vectors evaluated so far run the risk of random
transgene expression throughout the systemic vasculature.
Because the vectors have demonstrated the capacity for
transcytosis, virtually every cell within the body may be
susceptible to transduction. Even within the penis, it
would be beneficial to specify the transduction of a
particular cell phenotype, such as endothelial cells or
neuronsthe vectors evaluated so far have demonstrated
ecumenical transduction of diverse penile cells. Second,
owing to the costs involved in producing viral vectors, it
would be beneficial to find a way to limit the amount of
virus required to efficaciously transduce penile cells.
Limiting viral load requirements may also diminish the
risks of inflammation and resultant fibrosis.
Recent advancements in targeting viral vectors to
specific cell phenotypes may provide a solution to the
above concerns. In contrast to a virus that can
transduce an array of cell types, the specificity of these
vectors can be finely adjusted so that expression occurs within
a much more circumscribed set of cell types. If
specificity can be fine-tuned, it may become possible to
administer vectors systemically through intravenous
injection. The viral vectors could then target appropriate
cells without damaging non-targeted cells.
Transcriptional targeting has been advocated as one such method
of effecting specificity [61]. With transcriptional
targeting, promoters are selected that are uniquely expressed
within a particular cell type. That is, if smooth muscle
cells are targeted, then viral genes could be linked to the
promoter of desmin or some similar muscle-specific
promoter. The more restrictive the promoter, the more
specific the expression will be.
Alternatively, specificity could be realized through
transductional targeting [62]. With transductional
targeting, viral vectors are directed to transduce only those
cell types that express certain membrane markers.
Using this technique, it may be possible to preclude the
undesired transduction of non-targeted cells. Several
strategies have been suggested for achieving transductional
targeting in vivo, including pseudotyping, adaptor
systems, and genetic systems [63_65]. Concerning
potential therapies for ED, it may be possible to devise a
virus that specifically transduces target cells, thus
lowering required viral load and the risk of random transgene
expression. Such a highly specified vector would be
desirable for systemic delivery. Even if delivery
continued to be through intracavernous injection, a virus that
was either transcriptionally or transductionally targeted
may permit a more physiologically normal distribution of
gene expression. Increased specificity of cell type
expression may yield more natural responses to physiological
stimuli, thus enabling more normal erection physiology.
The true potential of gene therapy to mitigate or even
cure ED remains to be rigorously tested in a clinical
setting. Nevertheless, a very promising Phase I clinical
trial using plasmid-based gene delivery has shown that
gene therapy to the penis may be both safe and effective
in humans [16]. Combined with the flurry of preclinical
studies with viral-based gene therapy for ED, pioneering
studies such as this may lead to yet more efficacious
treatments for ED in the future.
4 Stem cell primer
Stem cells have garnered significant attention recently
for their suspected potential to treat currently intractable
diseases. While some of the more extravagant claims
are hyperbolic and excessively optimistic, there is clear
validity to the notion that stem cells may lead to novel
and potentially curative therapies. Resulting from age
and degenerative diseases, cells may wear out, becoming
dysfunctional or succumbing to apoptosis or necrosis.
Indeed, the etiological basis for several prominent
diseases, such as diabetes mellitus, sarcopenia of aging,
heart failure, and Parkinson's disease, is cell
dysfunction or loss [66_69]. For these and numerous other
maladies, pharmacotherapy may not be able to induce
the regenerative capacity of the remaining tissue.
Ostensibly, many conditions will benefit from a
treatment strategy that either transplants donor cells or
enhances the proliferative potential of tissue-resident stem
cells, thus functionally restoring the damaged tissues.
Although variably defined, stem cells are generally
attributed the capacity for 1) self-renewal, 2)
differentiation into one or more distinct phenotypes, and 3)
functional reproduction of damaged tissues [70]. Varying
stem cell populations fall along a gradient of
differentiation potential from those cells capable of becoming any
cell within the organism (pluripotent), to those with more
limited differentiation potential yet able of becoming
several distinct cell types (multipotent), to those with the
potential of becoming only one or a small number of cell
types (progenitor) [71_73]. While embryonic stem cells
within the inner cell mass are currently the only
well-acknowledged pluripotent stem cells, the adult human
has a number of multipotent and progenitor cell
populations residing within various tissues and organs for the
regular replacement of lost or failing cells [74].
5 Stem cell therapy for ED
Currently, only a very small number of studies have
evaluated the prospects of using stem cells to treat ED
[75_78], and cell-based therapy in general for treating
ED is quite new [79]. However, the potentially curative
nature of such treatments will undoubtedly encourage a
spate of forthcoming studies with varying stem cell
populations and strategies. Conceivably, stem cell therapies
may reasonably obviate the need to understand the
intricate molecular bases underlying ED. Current
pharmacological agents target precise biochemical pathways
within the penis that are aberrantly regulated under
certain disease states. Because there are a myriad of
potential mechanistic causes of ED, pharmacotherapy must
be able to treat each etiology uniquely by correcting
specific deviant pathways. By wholly replacing the
operative responsibilities of dysfunctional cells, repairing
specific molecular pathologies may not be critical. It is
certainly an oversimplification to discount the benefits of
elucidating the detailed molecular bases of ED, but much
of the exciting potential of stem cells rests in their
demonstrable capacity to either take over the function of
lost or damaged cells or secrete compounds in situ that
in some way normalize dysfunctional cells. Because
endothelial dysfunction of the penile vasculature is a
common cause of vasculogenic ED, rescuing the penile
endothelium with transplanted stem or progenitor cells may
functionally restore normal erectile responses in a large
number of ED cases. Presently, only mesenchymal stem
cells have been evaluated for their potential to treat
vasculogenic ED (Figure 1B) [77].
5.1 MSCs
Residing within the bone marrow and a number of
other tissue and organ reservoirs is a rare population of
multipotent stem cells called MSCs, which are uniquely
able to differentiate into a diverse array of cellular
phenotypes [80_84]. Because of their combined virtues of
robust proliferation, multipotency, and susceptibility to
genetic manipulation, MSCs have been studied vigorously
for their therapeutic potential. In preclinical studies, MSCs
have shown the ability to home to and repair damaged
tissues [85, 86], and clinical studies are currently
monitoring their capacity to remedy a number of pathological
conditions [87].
Given the right environment, MSCs have the
established capacity to differentiate into diverse cell types and
thus conceivably may be able to replace damaged or
dysfunctional tissues of the penis. MSCs can express
endothelial and smooth muscle phenotypes in
vitro and have been used successfully to repair vascular diseases and insults
in vivo, suggesting the possibility that this stem cell population
may be effective in replacing or rejuvenating the
dysfunctional analogous tissues within the penis [88_90].
At the present time, only two published studies are
known to have evaluated the potential for using MSCs to
treat vasculogenic ED [77, 78]. In the first of these
studies, Bivalacqua et al. [77] investigated the potential
of MSCs to differentiate into new endothelial cells and
improve endothelial-derived NO bioavailability and
erectile physiology. This and previous studies have
documented that rat MSCs can be readily transduced with an
Adv expressing eNOS and consequently express long-term high levels of eNOS protein, eNOS activity, and
cGMP concentrations [91, 92]. Aged rats with
demonstrable vasculogenic ED and reduced NO bioavailability
were given intracavernous injections of MSCs with or
without transduction with eNOS. Seven days after
injection the MSCs were adhered to the endothelium, and
after twenty-one days many of the cells were expressing
endothelial antigens. eNOS expression/activity, cGMP,
and erectile responses were significantly increased within
the penis after twenty-one days in both the normal and
transduced MSCs, suggesting the long-term capacity of
these cells to replace dysfunctional endothelial cells. In
addition, no signs of inflammation were noted at 7 and
21 days following injection of MSCs.
Subsequently, Song et al. [78] evaluated the
potential of immortalized human fetus-derived MSCs to
differentiate into endothelial and smooth muscle cells within
rat corpora cavernosa. The immortalized MSCs were
injected into the cavernosa of young, healthy rats, and
two weeks later the penes were collected and studied for
endothelial and smooth muscle antigens. Histological
assessment of the penes revealed the expression of
endothelial-specific antigens within the corpora,
suggesting that many of the MSCs had differentiated into
endothelial-like cells. Considered together, these two early
studies appear to provide evidence for the potential of
MSCs from various sources to differentiate into fully
functional endothelial cells and palliate both
endothelial-dependent NO bioavailability and erectile responses.
6 Conclusion
As the primary mediator of NO-derived smooth muscle relaxation, the penile endothelium is critical for
normal erectile physiology. Although PDE-5 inhibitors
are highly efficacious for a majority of men with ED, a
large contingent are unresponsive or have strict
contraindications to the drug and require alternative treatment
options. In addition, a drawback to oral pharmacotherapy
is the requirement for routine administration. Preclinical
gene and stem cell-based therapies demonstrate
apparent long-term efficacy in animal models. Already, gene
therapy for ED is being evaluated in clinical trials, and
stem cell-based approaches will likely follow. Combined
with the remarkable success of PDE-5 inhibitors,
endothelium-specific gene and stem cell-based therapies may
someday add to our growing armamentarium against ED.
References
1 NIH Consensus Conference. Impotence. NIH Consensus
Development Panel on Impotence. JAMA 1993; 270: 83_90.
2 Hurt KJ, Musicki B, Palese MA, Crone JK, Becker RE, Moriarity
JL, et al. Akt-dependent phosphorylation of endothelial
nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA
2002; 99: 4061_6.
3 Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom
WJ. Endothelial dysfunction in erectile dysfunction: role of the
endothelium in erectile physiology and disease. J Androl 2003;
24: S17_37.
4 Burnett AL. Erectile dysfunction. J Urol 2006; 175: S25_31.
5 Maas R, Schwedhelm E, Albsmeier J, Boger RH. The
pathophysiology of erectile dysfunction related to endothelial dysfunction
and mediators of vascular function. Vasc Med 2002; 7: 213_25.
6 Solomon H, Man JW, Jackson G. Erectile dysfunction and the
cardiovascular patient: endothelial dysfunction is the common
denominator. Heart 2003; 89: 251_3.
7 Watts GF, Chew KK, Stuckey BG. The erectile-endothelial
dysfunction nexus: new opportunities for cardiovascular risk
prevention. Nat Clin Pract Cardiovasc Med 2007; 4: 263_73.
8 Musicki B, Burnett AL. eNOS function and dysfunction within
the penis. Exp Biol Med 2006; 231: 154_65.
9 Rogers S. Reflections on issues posed by recombinant DNA
molecule technology. II. In: Lappe M, Morison RS,
editors. Ethical and Scientific Issues Posed by Human Uses of Molecular Genetics.
New York: New York Academy of Sciences; 1976. p66_70.
10 Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F,
Yvon E, Nusbaum P, et al. Gene therapy of human severe
combined immunodeficiency (SCID)-X1 disease. Science 2000; 288:
669_72.
11 Christ GJ, Melman A. The application of gene therapy to the
treatment of erectile dysfunction. Int J Impot Res 1998; 10: 111_2.
12 Bivalacqua TJ, Hellstrom WJ. Potential application of gene
therapy for the treatment of erectile dysfunction. J Androl 2001;
22: 183_90.
13 Kendirci M, Teloken PE, Champion HC, Hellstrom WJ,
Bivalacqua TJ. Gene therapy for erectile dysfunction: fact or
fiction? Eur Urol 2006; 50: 1208_22.
14 Bivalacqua TJ, Musicki B, Usta MF, Champion HC, Kadowitz PJ,
Burnett AL, et al. Endothelial nitric oxide synthase gene therapy
for erectile dysfunction. Curr Pharm Des 2005; 11: 4059_67.
15 Bivalacqua TJ, Kendirci M, Champion HC, Hellstrom WJ,
Andersson KE, Hedlund P. Dysregulation of cGMP-dependent
protein kinase 1 (PKG-1) impairs erectile function in diabetic
rats: influence of in vivo gene therapy of PKG1alpha. BJU Int
2007; 99: 1488_94.
16 Melman A, Bar-Chama N, McCullough A, Davies K, Christ G.
hMaxi-K gene transfer in males with erectile dysfunction: results
of the first human trial. Hum Gene Ther 2006; 17: 1165_76.
17 Shaul PW. Regulation of endothelial nitric oxide synthase: location,
location, location. Annu Rev Physiol 2002; 64: 749_74.
18 Lin CJ, Chao L, Chao J. Prolonged reduction of high blood
pressure with human nitric oxide synthase gene delivery.
Hypertension 1997; 30: 307_13.
19 Varenne O, Pislaru S, Gillijns H, Van Pelt N, Gerard RD, Zoldhelyi,
P, et al. Local adenovirus-mediated transfer of human
endothelial nitric oxide synthase reduces luminal narrowing after
coronary angioplasty in pigs. Circulation 1998; 98: 919_26.
20 Champion HC, Bivalacqua TJ, D'Souza FM, Ortiz LA, Jeter JR,
Toyoda K, et al. Gene transfer of endothelial nitric oxide synthase
to the lung of the mouse in vivo. Effect on agonist-induced and
flow-mediated vascular responses. Circ Res 1999; 84: 1422_32.
21 Champion HC, Bivalacqua TJ, Greenberg SS, Giles TD, Hyman
AL, Kadowitz PJ. Adenoviral gene transfer of endothelial
nitric-oxide synthase (eNOS) partially restores normal pulmonary
arterial pressure in eNOS-deficient mice. Proc Natl Acad Sci USA
2002; 99: 13248_53.
22 Cooney R, Hynes SO, Sharif F, Howard L, O'Brien T. Effect of
gene delivery of NOS isoforms on intimal hyperplasia and
endothelial regeneration after balloon injury. Gene Ther 2007; 14:
396_404.
23 Bivalacqua TJ, Champion HC, Mehta YS, Abdel-Mageed AB, Sikka
SC, Ignarro LJ, et al. Adenoviral gene transfer of endothelial nitric
oxide synthase (eNOS) to the penis improves age-related erectile
function in the rat. Int J Impot Res 2000; 12: S8_17.
24 Bivalacqua TJ, Usta MF, Champion HC, Adams D, Namara DB,
Abdel-Mageed AB, et al. Gene transfer of endothelial nitric oxide
synthase partially restores nitric oxide synthesis and erectile
function in streptozotocin diabetic rats. J Urol 2003; 169: 1911_7.
25 Bivalacqua TJ, Usta MF, Champion HC, Leungwattanakij S,
Dabisch PA, McNamara DB, et al. Effect of combination
endothelial nitric oxide synthase gene therapy and sildenafil on
erectile function in diabetic rats. Int J Impot Res 2004; 16: 21_9.
26 Burnett AL, Chang AG, Crone JK, Huang PL, Sezen SE.
Noncholinergic penile erection in mice lacking the gene for
endothelial nitric oxide synthase. J Androl 2002; 23: 92_7.
27 Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett
AL. Phosphodiesterase-5A dysregulation in penile erectile tissue
is a mechanism of priapism. Proc Natl Acad Sci USA 2005; 102:
1661_6.
28 Young LD, Bella A, Howard J, Brock G. Arteriogenic erectile
dysfunction alters protein expression within the cavernosal
tissue in an animal model. J Sex Med 2005; 2: 199_206.
29 Xie D, Kontos CD, Donatucci CF, Annex BH. Cholesterol
feeding reduces vascular endothelial growth factor signaling in rabbit
corporal tissues. J Sex Med 2005; 2: 634_40.
30 Ryu JK, Shin HY, Song SU, OH SM, Piao S, Han JY,
et al. Downregulation of angiogenic factors and their downstream target
molecules affects the deterioration of erectile function in a rat
model of hypercholesterolemia. Urology 2006; 67: 1329_34.
31 Henry GD, Byrne R, Hunyh TT, Abraham V, Annex BH, Hagen
PO, et al. Intracavernosal injections of vascular endothelial growth
factor protects endothelial dependent corpora cavernosal smooth
muscle relaxation in the hypercholesterolemic rabbit: a
preliminary study. Int J Impot Res 2000; 12: 334_9.
32 Gholami SS, Rogers R, Chang J, HO HC, Grazziottin T, Lin CS,
et al. The effect of vascular endothelial growth factor and
adeno-associated virus mediated brain derived neurotrophic factor on
neurogenic and vasculogenic erectile dysfunction induced by
hyperlipidemia. J Urol 2003; 169: 1577_81.
33 Lee MC, El-Sakka AI, Graziottin TM, Ho HC, Lin CS, Lue TF.
The effect of vascular endothelial growth factor on a rat model
of traumatic arteriogenic erectile dysfunction. J Urol 2002; 167:
761_7.
34 Lin CS, Ho HC, Chen KC, Lin G, Nunes L, Lue TF.
Intracavernosal injection of vascular endothelial growth factor
induces nitric oxide synthase isoforms. BJU Int 2002; 89: 955_60.
35 Yamanaka M, Shirai M, Shiina H, Tanaka Y, Enokida H, Tsujimura
A, et al. Vascular endothelial growth factor restores erectile
function through inhibition of apoptosis in diabetic rat penile crura.
J Urol 2005; 173: 318_23.
36 Shirai M, Yamanaka M, Shiina H, Igawa M, Kawakami T, Ishii N,
et al. Vascular endothelial growth factor restores erectile
function through modulation of the insulin-like growth factor system
and sex hormone receptors in diabetic rat. Biochem Biophys Res
Commun 2006; 341: 755_62.
37 Musicki B, Palese MA, Crone JK, Burnett AL. Phosphorylated
endothelial nitric oxide synthase mediates vascular endothelial
growth factor-induced penile erection. Biol Reprod 2004; 70:
282_9.
38 Rogers RS, Graziottin TM, Lin CS, Kan YW, Lue TF.
Intracavernosal vascular endothelial growth factor (VEGF) injection
and adeno-associated virus-mediated VEGF gene therapy
prevent and reverse venogenic erectile dysfunction in rats. Int J
Impot Res 2003; 15: 26_37.
39 Ryu JK, Cho CH, Shin HY, Song SU, Oh SM, Lee M,
et al. Combined angiopoietin-1 and vascular endothelial growth factor
gene transfer restores cavernous angiogenesis and erectile
function in a rat model of hypercholesterolemia. Mol Ther 2006; 13:
705_15.
40 Agarwal A, Nandipati KC, Sharma RK, Zippe CD, Raina R. Role
of oxidative stress in the pathophysiological mechanism of
erectile dysfunction. J Androl 2006; 27: 335_47.
41 Xu J, He L, Ahmed SH, Chen SW, Goldberg MP, Beckman JS,
et al. Oxygen-glucose deprivation induces inducible nitric oxide
synthase and nitrotyrosine expression in cerebral endothelial
cells. Stroke 2000; 31: 1744_51.
42 Fennell JP, Brosnan MJ, Frater AJ, Hamilton CA, Alexander
MY, Nicklin SA, et al. Adenovirus-mediated overexpression of
extracellular superoxide dismutase improves endothelial
dysfunction in a rat model of hypertension. Gene Ther 2002; 9: 110_7.
43 Zanetti M, Sato J, Jost CJ, Gloviczki P, Katusic ZS, O'Brien T.
Gene transfer of manganese superoxide dismutase reverses
vascular dysfunction in the absence but not in the presence of
atherosclerotic plaque. Hum Gene Ther 2001; 12: 1407_16.
44 Iida S, Chu Y, Francis J, Weiss RM, Gunnett CA, Faraci FM,
et al. Gene transfer of extracellular superoxide dismutase improves
endothelial function in rats with heart failure. Am J Physiol
Heart Circ Physiol 2005; 289: H525_32.
45 Brown KA, Chu Y, Lund DD, Heistad DD, Faraci FM. Gene
transfer of extracellular superoxide dismutase protects against
vascular dysfunction with aging. Am J Physiol Heart Circ Physiol
2006; 290: H2600_5.
46 Bivalacqua TJ, Armstrong JS, Biggerstaff J, Abdel-Mageed AB,
Kadowitz PJ, Hellstrom WJ. Gene transfer of extracellular SOD to
the penis reduces superoxide and improves erectile function in
aged rats. Am J Physiol Heart Circ Physiol 2003; 284: H1408_21.
47 De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH,
Vanhoutte PM. Endothelial dysfunction in diabetes. Br J
Pharmacol 2000; 130: 963_74.
48 Channon KM, Guzik TJ. Mechanisms of superoxide productin in
human blood vessels: Relationship to endothelial dysfunction,
clinical and genetic risk factors. J Physiol Pharmacol 2002; 53:
515_24.
49 Akingba AG, Burnett AL. Endothelial nitric oxide synthase
protein expression, localization, and activity in the penis of the
alloxan-induced diabetic rat. Mol Urol 2001; 5: 189_97.
50 Podlasek CA, Zelner DJ, Bervig TR, Gonzalez CM, McKenna
KE, McVary KT. Characterization and localization of nitric
oxide synthase isoforms in the BB/WOR diabetic rat. J Urol 2001;
166: 746_55.
51 Bivalacqua TJ, Usta MF, Kendirci M, Pradhan L, Alvarez X,
Champion HC, et al. Superoxide anion production in the rat
penis impairs erectile function in diabetes: influence of in vivo
extracellular superoxide dismutase gene therapy. J Sex Med 2005;
2: 187_97.
52 Christ GJ, Rehman J, Day N, Salkoff L, Valcic M, Melman A,
et al. Intracorporal injection of hSlo cDNA in rats produces
physiologically relevant alterations in penile function. Am J Physiol
1998; 275: H600_8.
53 Bakircioglu ME, Lin CS, Fan P, Sievert KD, Kan YW, Lue TF.
The effect of adeno-associated virus mediated brain derived
neurotrophic factor in an animal model of neurogenic impotence. J
Urol 2001; 165: 2103_9.
54 Bivalacqua TJ, Champion HC, Abdel-Mageed AB, Kadowitz PJ,
Hellstrom WJ. Gene transfer of prepro-calcitonin gene-related
peptide restores erectile function in the aged rat. Biol Reprod
2001; 65: 1371_7.
55 Magee TR, Ferrini M, Garban HJ, Vernet D, Mitani K, Rajfer J,
et al. Gene therapy of erectile dysfunction in the rat with penile
neuronal nitric oxide synthase. Biol Reprod 2002; 67: 20_8.
56 Shen ZJ, Wang H, Lu YL, Zhou XL, Chen SW, Chen ZD. Gene
transfer of vasoactive intestinal polypeptide into the penis
improves erectile response in the diabetic rat. BJU Int 2005; 95:
890_4.
57 Pu XY, Hu LQ, Wang HP, Luo YX, Wang XH. Improvement in
erectile dysfunction after insulin-like growth factor-1 gene
therapy in diabetic rats. Asian J Androl 2007; 9: 83_91.
58 Garban H, Marquez D, Magee T, Moody J, Rajavashisth T,
Rodriguez JA, et al. Cloning of rat and human inducible penile
nitric oxide synthase. Application for gene therapy of erectile
dysfunction. Biol Reprod 1997; 56: 954_63.
59 Gonzalez-Cadavid NF, Rajfer J. The pleiotropic effects of
inducible nitric oxide synthase (iNOS) on the physiology and
pathology of penile erection. Curr Pharm Des 2005; 11: 4041_6.
60 Wessels H, Teal TH, Luttrell IP, Sullivan CJ. Effect of
endothelial cell-based iNOS gene transfer on cavernosal eNOS expression
and mouse erectile responses. Int J Impot Res 2006; 18: 438_45.
61 Sadeghi H, Hitt MM. Transcriptionally targeted adenovirus
vectors. Curr Gene Ther 2005; 5: 411_27.
62 Waehler R, Russell SJ, Curiel DT. Engineering targeted viral
vectors for gene therapy. Nat Rev Genet 2007; 8: 573_87.
63 Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral
vectors through pseudotyping. Curr Gene Ther 2005; 5: 387_98.
64 Pereboev AV, Nagle JM, Shakhmatov MA, Triozzi PL, Matthews
QL, Kawakami Y, et al. Enhanced gene transfer to mouse
dendritic cells using adenoviral vectors coated with a novel adapter
molecule. Mol Ther 2004; 9: 712_20.
65 Mahasreshti PJ, Kataram M, Wu H, Yalavarthy LP, Carey D,
Fisher PB, et al. Ovarian cancer targeted adenoviral-mediated
mda-7/IL-24 gene therapy. Gynecol Oncol 2006; 100: 521_32.
66 Lee SC, Pervaiz S. Apoptosis in the pathophysiology of diabetes
mellitus. Int J Biochem Cell Biol 2007; 39: 497_504.
67 Marzetti E, Leeuwenburgh C. Skeletal muscle apoptosis, sarcopenia
and frailty at old age. Exp Gerontol 2006; 41: 1234_8.
68 Grazzette LP, Rosenzweig A. Role of apoptosis in heart failure.
Heart Fail Clin 2005; 1: 251_61.
69 Bredesen DE, Rao RV, Mehlen P. Cell death in the nervous
system. Nature 2006; 443: 796_802.
70 Morrison SJ, Shah NM, Anderson DJ. Regulatory mechanisms in
stem cell biology. Cell 1997; 88: 287_98.
71 Hoffman JA, Merrill BJ. New and renewed perspectives on
embryonic stem cell pluripotency. Front Biosci
2007; 12: 3321_32.
72 Spangrude GJ, Heimfeld S, Weissman IL. Purification and
characterization of mouse hematopoietic stem cells. Science 1988;
241: 58_62.
73 Weissman IL, Anderson DJ, Gage F. Stem and progenitor cells:
origins, phenotypes, lineage commitments, and
transdifferentiations. Annu Rev Cell Dev Biol 2001; 387_403.
74 Harley CB, Rao MS. Human embryonic vs adult stem cells for
transplantation therapies. In: Chiu AY, Rao MS, editors. Human
Embryonic Stem Cells. Totowa: Humana Press; 2003. p239_64.
75 Bochinski D, Lin GT, Nunes L, Carrion R, Rahman N, Lin CS,
et al. The effect of neural embryonic stem cell therapy in a rat
model of cavernosal nerve injury. BJU Int 2004; 94: 904_9.
76 Kim Y, de Miguel F, Usiene I, Kwon D, Yoshimura N, Huard J,
et al. Injection of skeletal muscle-derived cells into the penis
improves erectile function. Int J Impot Res 2006; 18: 329_34.
77 Bivalacqua TJ, Deng W, Kendirci M, Usta MF, Robinson C,
Taylor BK, et al. Mesenchymal stem cells alone or
ex vivo gene modified with endothelial nitric oxide synthase reverse
age-associated erectile dysfunction. Am J Physiol Heart Circ Physiol
2007; 292: H1278_H90.
78 Song YS, Lee HJ, Park IH, Kim WK, Ku JH, Kim SU. Potential
differentiation of human mesenchymal stem cell transplanted in
rat corpus cavernosum toward endothelial or smooth muscle
cells. Int J Impot Res 2007; 19: 378_85.
79 Wessels H, Williams SK. Endothelial cell transplantation into
the corpus cavernosum: moving towards cell-based gene therapy.
J Urol 1999; 162: 2162_4.
80 Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R,
Mosca JD, et al. Multilineage potential of adult human
mesenchymal stem cells. Science 1999; 284: 143_7.
81 Kopen G, Prockop D, Phinney D. Marrow stromal cells migrate
throughout forebrain and cerebellum, and they differentiate into
astrocytes after injection into neonatal mouse brains. Proc Natl
Acad Sci U S A 1999; 96: 10711_6.
82 Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski
N, et al. Mesenchymal stem cell engraftment in lung is enhanced
in response to bleomycin exposure and ameliorates its fibrotic
effects. Proc Natl Acad Sci U S A 2003; 100: 8407_11.
83 Aurich I, Mueller LP, Aurich H, Leutzkendorf J, Tisljar K,
Dollinger MM, et al. Functional integration of hepatocytes
derived from human mesenchymal stem cells into mouse livers.
Gut 2007; 56: 405_15.
84 da Silva Mereilles L, Chagastelles PC, Nardi NB. Mesenchymal
stem cells reside in virtually all post-natal organs and tissues. J
Cell Sci 2006; 119: 2204_13.
85 Jiang W, Ma A, Wang T, Han K, Liu Y, Zhang Y,
et al. Homing and differentiation of mesenchymal stem cells delivered
intravenously to ischemic myocardium in
vivo: a time-series study. Pflugers Arch 2006; 453: 43_52.
86 Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M,
et al. Intravenous administration of mesenchymal stem cells improves
cardiac function in rats with acute myocardial infarction through
angiogenesis and myogenesis. Am J Physiol Heart Circ
Physiol 2004; 287: H2670_6.
87 Giordano A, Galderisi U, Marino IR. From the laboratory bench
to the patient's bedside: an update on clinical trials with
mesenchymal stem cells. J Cell Physiol 2007; 211: 27_35.
88 Wu X, Huang L, Zhou Q, Song Y, Li A, Jin J,
et al. Mesenchymal stem cells participating in ex vivo endothelium repair and its
effect on vascular smooth muscle cells growth. Int J Cardiol
2005; 105: 274_82.
89 Wang T, Xu Z, Jiang W, Ma A. Cell-to-cell contact induces
mesenchymal stem cell to differentiate into cardiomyocyte and
smooth muscle cell. Int J Cardiol 2006; 109: 74_81.
90 Kim SW, Han H, Chae GT, Lee SH, Bo S, Yoon JH,
et al. Successful stem cell therapy using umbilical cord blood-derived
multipotent stem cells for Buerger's disease and ischemic limb
disease animal model. Stem Cells 2006; 24: 1620_6.
91 Deng W, Bivalacqua TJ, Chattergoon NN, Hyman AL, Jeter JR
Jr., Kadowitz PJ. Adenoviral gene transfer of eNOS: high-level
expression in ex vivo expanded marrow stromal cells. Am J
Physiol Cell Physiol 2003; 285: C1322_9.
92 Bivalacqua TJ, Deng W, Champion HC, Hellstrom WJ, Kadowitz
PJ. Gene therapy techniques for the delivery of endothelial nitric
oxide synthase to the corpora cavernosa for erectile dysfunction.
Methods Mol Biol 2004; 279: 173_85.
|